|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-12-18
|
|
pubmed:abstractText |
Osteoprotegerin (OPG) has been identified as a decoy receptor that inhibits osteoclast differentiation and, more recently, as a paracrine regulator of vascular calcification. OPG is suppressed by glucocorticoids (GC); however, results from experimental and clinical studies are not univocal. The aim of this study was to evaluate OPG and bone metabolism in patients with Cushing's syndrome (CS) before and after cure.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1479-683X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
162
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
85-90
|
|
pubmed:meshHeading |
pubmed-meshheading:19793762-Adolescent,
pubmed-meshheading:19793762-Adult,
pubmed-meshheading:19793762-Aged,
pubmed-meshheading:19793762-Bone Density,
pubmed-meshheading:19793762-Cushing Syndrome,
pubmed-meshheading:19793762-Female,
pubmed-meshheading:19793762-Humans,
pubmed-meshheading:19793762-Hydrocortisone,
pubmed-meshheading:19793762-Longitudinal Studies,
pubmed-meshheading:19793762-Middle Aged,
pubmed-meshheading:19793762-Osteoprotegerin,
pubmed-meshheading:19793762-Retrospective Studies,
pubmed-meshheading:19793762-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Persistent increase of osteoprotegerin levels after cortisol normalization in patients with Cushing's syndrome.
|
|
pubmed:affiliation |
Division of Endocrinology, Department of Medical and Surgical Sciences, University of Padova, Padova, Italy.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
